Table 3. Odds ratios for breast cancer risk by lymph node involvement*.
| Locus | Cases with negative nodes | Cases with positive nodes | Observed | Adjusted | ||||||
| SNP | Genotype | Controls | N | OR** | 95% CI | N | OR** | 95% CI | P*** | P**** |
| FGFR2 | GG | 7494 | 3031 | 1.00 | 1683 | 1.00 | ||||
| rs2981582 | AG | 9021 | 4539 | 1.23 | 1.16–1.30 | 2753 | 1.32 | 1.23–1.42 | ||
| AA | 2746 | 1734 | 1.56 | 1.44–1.68 | 1104 | 1.77 | 1.61–1.94 | |||
| per allele | 1.25 | 1.20–1.29 | 1.33 | 1.27–1.39 | 0.013 | 0.41 | ||||
| TNRC9 | GG | 9762 | 4234 | 1.00 | 2470 | 1.00 | ||||
| rs3803662 | AG | 7180 | 3930 | 1.22 | 1.16–1.29 | 2391 | 1.26 | 1.18–1.34 | ||
| AA | 1551 | 1028 | 1.36 | 1.24–1.49 | 639 | 1.35 | 1.21–1.51 | |||
| per allele | 1.19 | 1.14–1.24 | 1.20 | 1.14–1.26 | 0.78 | 1.00 | ||||
| MAP3K1 | TT | 9867 | 4547 | 1.00 | 2707 | 1.00 | ||||
| rs889312 | GT | 7753 | 3864 | 1.11 | 1.05–1.17 | 2291 | 1.11 | 1.04–1.19 | ||
| GG | 1656 | 919 | 1.23 | 1.12–1.35 | 572 | 1.32 | 1.18–1.48 | |||
| per allele | 1.11 | 1.06–1.15 | 1.14 | 1.08–1.19 | 0.31 | 1.00 | ||||
| 8q24 | AA | 5257 | 2607 | 1.00 | 1634 | 1.00 | ||||
| rs13281615 | AG | 7316 | 3921 | 1.11 | 1.04–1.18 | 2372 | 1.08 | 1.00–1.17 | ||
| GG | 2741 | 1635 | 1.23 | 1.13–1.33 | 961 | 1.22 | 1.11–1.35 | |||
| per allele | 1.11 | 1.07–1.15 | 1.10 | 1.05–1.16 | 0.95 | 1.00 | ||||
| LSP1 | AA | 9357 | 4531 | 1.00 | 2708 | 1.00 | ||||
| rs381798 | AG | 8148 | 3917 | 1.03 | 0.98–1.09 | 2318 | 1.05 | 0.98–1.12 | ||
| GG | 1749 | 866 | 1.11 | 1.02–1.22 | 534 | 1.20 | 1.07–1.34 | |||
| per allele | 1.05 | 1.01–1.09 | 1.08 | 1.03–1.13 | 0.38 | 1.00 | ||||
*: Analyses excluded data from three studies (GESBC, MCBCS and SEARCH) without information on node involvement.
**: Per-allele OR adjusted for study.
***: P value for heterogeneity of ORs from case-only analyses adjusted by study.
****: Permutation adjusted P for heterogeneity.